Quantum Computing (QUBT) Is Down 6.0% After Russell Additions And NeuraWave Deal News – Has The Bull Case Changed?

• In June 2026, Quantum Computing Inc. (NasdaqCM:QUBT) was added to several Russell value and small-cap benchmarks, and earlier that month it announced a framework agreement with Planck Dynamics that includes an initial order for five NeuraWave photonic reservoir computing systems and a potential program value above US$10 million, subject to milestones.
• This combination of index inclusion and a commercial framework for NeuraWave underscores how Quantum Computing Inc. is gaining broader capital markets visibility while starting to convert its photonic AI technology into structured, milestone-based deployment opportunities.
• Against this backdrop, we’ll examine how Quantum Computing Inc.’s Russell index inclusions might influence its evolving investment narrative and perceived market positioning.

The latest GPUs need a type of rare earth metal called Terbium and there are only 30 companies in the world exploring or producing it. Find the list for free.

Quantum Computing Investment Narrative Recap

To own Quantum Computing Inc., you have to believe that room temperature photonic systems and NeuraWave can move from pilots to repeatable, scaled deployments while the company manages rising costs and early stage revenue. The Planck Dynamics framework and Russell index inclusions both support visibility, but they do not remove the short term risk that operating expenses keep outpacing revenue or that anticipated AI and quantum use cases take longer to translate into durable contracts.

Among recent announcements, the Planck Dynamics agreement is most directly relevant. It gives NeuraWave a concrete commercial context, with an initial order for five systems in 2026 and a milestone based path to more than US$10 million in potential program value. For investors focused on catalysts, this deal is an early test of whether QCi can turn its photonic AI at the edge positioning into a repeatable revenue model rather than a series of one off pilot wins.

Yet alongside these positives, the company’s fast rising cost base and dependence on milestone based deals remain issues investors should be aware of, especially if...

Read the full narrative on Quantum Computing (it's free!)

Quantum Computing's narrative projects $17.3 million revenue and $1.1 million earnings by 2028. This requires 216.2% yearly revenue growth and about a $69.5 million earnings increase from -$68.4 million today.

Uncover how Quantum Computing's forecasts yield a $23.67 fair value, a 139% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenue could reach about US$56.3 million by 2029, which is far more bullish than the cautious view that QCi might struggle to build a broad customer base if adoption of its quantum and AI hardware is slow, so this new framework and index inclusion may either reinforce that optimism or prompt you to rethink how realistic those expectations really are.

Explore 14 other fair value estimates on Quantum Computing - why the stock might be worth less than half the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Quantum Computing research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Quantum Computing research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Quantum Computing's overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 42 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com